Glenmark Pharma vs Gland Pharma vs Emcure Pharma: Which Stock Should You Track
- September 28, 2026
- Posted by: Chaitanya Auti
- Category: Market
Glenmark Pharmaceuticals PE 37.41, mkt cap Rs 67,254 crore. Gland Pharma PE 42.62, mkt cap Rs 48,107 crore. Emcure Pharmaceuticals PE 36.22, mkt cap Rs 36,902 crore.
Quick Answer
Glenmark Pharmaceuticals vs Gland Pharma vs Emcure Pharmaceuticals is a side-by-side comparison of three companies from the Pharma Formulations space. On this comparison, Glenmark Pharmaceuticals carries a market capitalisation of about Rs 67,254 crore against Rs 48,107 crore for Gland Pharma and Rs 36,902 crore for Emcure Pharmaceuticals, with return on equity of 28.08%, 9.92% and 18.67% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.
Glenmark Pharmaceuticals vs Gland Pharma vs Emcure Pharmaceuticals starts with the core numbers most investors compare within the Pharma Formulations segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.
All three names sit in the Pharma Formulations bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.
Click Here – Get Free Investment Predictions
Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals: Company Overview
Glenmark Pharmaceuticals is a listed Indian company in the Pharma Formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Gland Pharma is a listed Indian company in the Pharma Formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Emcure Pharmaceuticals is a listed Indian company in the Pharma Formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Glenmark Pharmaceuticals vs Gland Pharma vs Emcure Pharmaceuticals: Valuation and Profitability Snapshot
| Metric | Glenmark Pharmaceuticals | Gland Pharma | Emcure Pharmaceuticals |
|---|---|---|---|
| Market Cap (approx.) | Rs 67,254 crore | Rs 48,107 crore | Rs 36,902 crore |
| PE Ratio (TTM) | 37.41 | 42.62 | 36.22 |
| PB Ratio | 6.40 | 4.64 | 7.45 |
| Return on Equity (ROE) | 28.08% | 9.92% | 18.67% |
| EPS (TTM, Rs) | 63.70 | 68.41 | 53.71 |
| Dividend Yield | 0.21% | 0.69% | 0.18% |
| Debt to Equity | 0.06 | 0.03 | 0.31 |
| Book Value per Share (Rs) | 372.47 | 627.71 | 260.93 |
Check the Univest Screener for Live Data
On valuation, Glenmark Pharmaceuticals trades at a PE of 37.41 and a PB of 6.40, Gland Pharma at a PE of 42.62 and a PB of 4.64, while Emcure Pharmaceuticals trades at a PE of 36.22 and a PB of 7.45. On return on equity, the three post 28.08%, 9.92% and 18.67% respectively, and on dividend yield they stand at 0.21%, 0.69% and 0.18%.
Glenmark Pharmaceuticals vs Gland Pharma vs Emcure Pharmaceuticals: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) |
|---|---|---|---|---|
| Glenmark Pharmaceuticals | Rs 4,084.24 crore | Rs 482.83 crore | +24.1% | +3.1% |
| Gland Pharma | Rs 1,861.50 crore | Rs 316.96 crore | +19.1% | +0.4% |
| Emcure Pharmaceuticals | Rs 2,582.52 crore | Rs 292.49 crore | +22.7% | +4.4% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter.
Download the Univest iOS App or Univest Android App to track Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three pharma formulations names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.
Conclusion
Glenmark Pharmaceuticals vs Gland Pharma vs Emcure Pharmaceuticals highlights how differently three companies in the same pharma formulations segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of September 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Glenmark Pharmaceuticals vs Gland Pharma vs Emcure Pharmaceuticals
What is the market cap difference between Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals?
Ans. As of September 2026, Glenmark Pharmaceuticals has a market cap of approximately Rs 67,254 crore, Gland Pharma is at approximately Rs 48,107 crore, and Emcure Pharmaceuticals is at approximately Rs 36,902 crore.
Which of the three has the highest PE ratio?
Ans. Among Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals, the PE ratios stand at 37.41, 42.62 and 36.22 respectively as of September 2026.
Which of the three has the highest ROE?
Ans. Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals post ROE of 28.08%, 9.92% and 18.67% respectively as of September 2026.
Which of these three stocks pays the highest dividend yield?
Ans. Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals carry dividend yields of 0.21%, 0.69% and 0.18% respectively.
What is the debt to equity ratio for Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals?
Ans. Glenmark Pharmaceuticals carries a debt to equity of 0.06, Gland Pharma of 0.03, and Emcure Pharmaceuticals of 0.31.
Which of the three trades at the highest price to book value?
Ans. Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals trade at price to book ratios of 6.40, 4.64 and 7.45 respectively.
Is one of Glenmark Pharmaceuticals, Gland Pharma or Emcure Pharmaceuticals better than the others?
Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research.